These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 24732866)

  • 21. [Therapy spectrum in hepatitis C extended. Newer NS3/4A protease inhibitor in chronic hepatitis C-GT1/4 infection].
    MMW Fortschr Med; 2014 Jun; 156 Suppl 1():53. PubMed ID: 25026860
    [No Abstract]   [Full Text] [Related]  

  • 22. The comparative clinical effectiveness and value of simeprevir and sofosbuvir for chronic hepatitis C virus infection.
    Ollendorf DA; Tice JA; Pearson SD
    JAMA Intern Med; 2014 Jul; 174(7):1170-1. PubMed ID: 24798321
    [No Abstract]   [Full Text] [Related]  

  • 23. HCV F1/F2 patients: treat now or continue to wait.
    Shiffman ML; Benhamou Y
    Liver Int; 2014 Feb; 34 Suppl 1():79-84. PubMed ID: 24373082
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sofosbuvir (GS-7977), a pan-genotype, direct-acting antiviral for hepatitis C virus infection.
    Rodríguez-Torres M
    Expert Rev Anti Infect Ther; 2013 Dec; 11(12):1269-79. PubMed ID: 24215243
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [A new era in therapy of chronic hepatitis C].
    Füessl HS
    MMW Fortschr Med; 2015 Feb; 157(2):38. PubMed ID: 25743515
    [No Abstract]   [Full Text] [Related]  

  • 26. Recent advances in the treatment of hepatitis C.
    Dhingra A; Kapoor S; Alqahtani SA
    Discov Med; 2014 Oct; 18(99):203-8. PubMed ID: 25336034
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hepatitis C genotype 1.
    Foster GR; De Silva S
    Curr Opin Infect Dis; 2014 Dec; 27(6):535-9. PubMed ID: 25304394
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of chronic hepatitis C virus infection in the near future.
    Cheinquer H
    Ann Hepatol; 2013; 12(6):854-9. PubMed ID: 24114813
    [No Abstract]   [Full Text] [Related]  

  • 29. Sofosbuvir, simeprevir, and ribavirin for the treatment of hepatitis C virus recurrence in human immunodeficiency virus/hepatitis C virus-coinfected liver transplant recipients.
    Campos-Varela I; Straley S; Agudelo EZ; Carlson L; Terrault NA
    Liver Transpl; 2015 Feb; 21(2):272-4. PubMed ID: 25332190
    [No Abstract]   [Full Text] [Related]  

  • 30. Second-wave IFN-based triple therapy for HCV genotype 1 infection: simeprevir, faldaprevir and sofosbuvir.
    Asselah T; Marcellin P
    Liver Int; 2014 Feb; 34 Suppl 1():60-8. PubMed ID: 24373080
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Chronic hepatitis C. Interferon free therapy also in patients with liver cirrhosis].
    MMW Fortschr Med; 2014 Dec; 156(21-22):97. PubMed ID: 25608420
    [No Abstract]   [Full Text] [Related]  

  • 32. Review article: 2014 UK consensus guidelines - hepatitis C management and direct-acting anti-viral therapy.
    Miller MH; Agarwal K; Austin A; Brown A; Barclay ST; Dundas P; Dusheiko GM; Foster GR; Fox R; Hayes PC; Leen C; Millson C; Ryder SD; Tait J; Ustianowski A; Dillon JF; ; ; ; ; ;
    Aliment Pharmacol Ther; 2014 Jun; 39(12):1363-75. PubMed ID: 24754233
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Different viral kinetics between hepatitis C virus genotype 1 and 2 as on-treatment predictors of response to a 24-week course of high-dose interferon-alpha plus ribavirin combination therapy.
    Yu ML; Chuang WL; Dai CY; Lee LP; Hsieh MY; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Tsai SL; Kuo HT
    Transl Res; 2006 Sep; 148(3):120-7. PubMed ID: 16938649
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New drugs: simeprevir, sofosbuvir, and dolutegravir sodium.
    Hussar DA; Jin ZJ
    J Am Pharm Assoc (2003); 2014; 54(2):202-7. PubMed ID: 24632934
    [No Abstract]   [Full Text] [Related]  

  • 35. Dutch guidance for the treatment of chronic hepatitis C virus infection in a new therapeutic era.
    Berden FA; Kievit W; Baak LC; Bakker CM; Beuers U; Boucher CA; Brouwer JT; Burger DM; van Erpecum KJ; van Hoek B; Hoepelman AI; Honkoop P; Kerbert-Dreteler MJ; de Knegt RJ; Koek GH; van Nieuwkerk CM; van Soest H; Tan AC; Vrolijk JM; Drenth JP
    Neth J Med; 2014 Oct; 72(8):388-400. PubMed ID: 25387551
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevalence of drug-drug interactions upon addition of simeprevir- or sofosbuvir-containing treatment to medication profiles of patients with HIV and hepatitis C coinfection.
    Patel N; Nasiri M; Koroglu A; Amin R; McGuey L; McNutt LA; Roman M; Miller C
    AIDS Res Hum Retroviruses; 2015 Feb; 31(2):189-97. PubMed ID: 25432275
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The high price of the new hepatitis C virus drugs.
    Steinbrook R; Redberg RF
    JAMA Intern Med; 2014 Jul; 174(7):1172. PubMed ID: 24798183
    [No Abstract]   [Full Text] [Related]  

  • 38. Assessing safety and efficacy of sofosbuvir for the treatment of hepatitis C.
    D'Ambrosio R; Aghemo A; Colombo M
    Expert Opin Drug Saf; 2015 Mar; 14(3):473-84. PubMed ID: 25645644
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [New combination therapy increases chances of recovery].
    Jäger-Becker D
    MMW Fortschr Med; 2015 Feb; 157(3):70. PubMed ID: 25743682
    [No Abstract]   [Full Text] [Related]  

  • 40. Changing the face of hepatitis C management - the design and development of sofosbuvir.
    Noell BC; Besur SV; deLemos AS
    Drug Des Devel Ther; 2015; 9():2367-74. PubMed ID: 25987834
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.